Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Venofer
Generic Name
Iron Sucrose
Active Ingredient
Iron SucroseCategory
Parenteral Iron Replacement [EPC]
Variants
6
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Venofer, you must consult a qualified healthcare professional.
| 20 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 0517-2340 |
| 20 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 49230-530 |
Detailed information about Venofer
Iron Sucrose is a sterile, aqueous complex of polynuclear iron (III)-hydroxide in sucrose used for the intravenous treatment of iron deficiency anemia, particularly in patients with chronic kidney disease (CKD). It belongs to the parenteral iron replacement class of medications.
The dosage of Iron Sucrose is highly individualized and depends on the patient's body weight, hemoglobin levels, and the specific stage of chronic kidney disease (CKD). Healthcare providers typically aim to reach a cumulative dose of 1,000 mg of elemental iron to replenish stores.
Iron Sucrose is FDA-approved for the treatment of iron deficiency anemia in pediatric patients aged 2 years and older who have CKD.
Since Iron Sucrose is primarily indicated for patients with renal impairment, no specific dose adjustment is required for the degree of kidney failure itself. However, the timing of administration is often synchronized with dialysis schedules.
Caution is advised in patients with severe liver dysfunction. The liver is a primary storage site for iron (as ferritin). In patients with hepatitis or cirrhosis, the risk of iron overload or oxidative stress may be increased. Healthcare providers will monitor liver function tests and iron parameters closely.
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Iron Sucrose must be administered by a healthcare professional in a clinical setting equipped to handle emergency allergic reactions. It is never self-administered.
Because Iron Sucrose is administered by healthcare professionals in a clinic or dialysis center, a missed dose usually involves a missed appointment. If you miss a scheduled session, contact your healthcare provider immediately to reschedule. Maintaining the schedule is vital for the effective replenishment of iron stores.
An overdose of Iron Sucrose can lead to acute iron toxicity. Symptoms may include:
In the event of a suspected overdose, emergency measures include supportive care and, in severe cases, the use of iron-chelating agents (medications that bind to iron to help the body excrete it).
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Regular blood tests are necessary to ensure iron levels remain within a safe range.
Most patients tolerate Iron Sucrose well, but some may experience mild to moderate side effects. Common reactions include:
Iron Sucrose is a potent medication that must be administered with caution. The most critical safety concern is the risk of hypersensitivity reactions, including anaphylaxis. Patients should be monitored for at least 30 minutes following each injection to ensure no delayed reactions occur. Because it is administered intravenously, the onset of side effects can be rapid. Healthcare providers must have resuscitation equipment and emergency medications (like epinephrine and antihistamines) immediately available.
No FDA black box warnings for Iron Sucrose. While it is considered safer than iron dextran, the potential for serious allergic reactions remains a primary clinical focus.
Iron Sucrose must NEVER be used in the following circumstances:
Conditions requiring careful risk-benefit analysis include:
Iron Sucrose is classified as Pregnancy Category B (under the old FDA system). This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.
Sucrose is a natural component of the body, and iron is naturally present in breast milk. Limited data suggest that the amount of iron that passes into breast milk following an IV Iron Sucrose infusion is minimal and unlikely to cause adverse effects in the nursing infant. However, mothers should monitor the infant for potential constipation or changes in stool color.
Iron Sucrose is an iron replacement product that delivers iron in a form that mimics the body's natural iron-storage proteins. It is a complex of polynuclear iron(III)-hydroxide cores. These cores are non-covalently surrounded by sucrose molecules.
Upon intravenous administration, the complex remains stable in the plasma until it is engulfed by macrophages of the reticuloendothelial system (RES). Within the lysosomes of these macrophages, the acidic environment and enzymes break the complex apart. The iron is then released into the intracellular pool. From here, it can be stored as ferritin or transported out of the cell via ferroportin. Once in the blood, it binds to transferrin, which delivers it to the bone marrow for incorporation into hemoglobin during the maturation of red blood cells.
The pharmacodynamic response to Iron Sucrose is measurable by an increase in reticulocyte count (new red blood cells) within 7-10 days of starting therapy, followed by a rise in hemoglobin and hematocrit levels. The duration of effect depends on the patient's rate of iron loss (e.g., through ongoing dialysis or bleeding) and the rate of erythropoiesis. There is no evidence of tolerance development; the body continues to utilize the iron as long as a deficiency exists.
Common questions about Venofer
Iron Sucrose is primarily used to treat iron deficiency anemia in patients with chronic kidney disease (CKD). This includes patients who are on hemodialysis, peritoneal dialysis, or those who are not yet dialysis-dependent. It works by replenishing the body's iron stores, which are essential for producing hemoglobin and healthy red blood cells. Because CKD patients often cannot absorb enough iron from their diet or oral supplements, this intravenous form is necessary. It is also used off-label for other types of severe iron deficiency when oral treatments fail.
The most common side effects reported by patients receiving Iron Sucrose include low blood pressure (hypotension), nausea, dizziness, and headache. Many patients also experience muscle cramps, particularly if they are receiving the infusion during a dialysis session. A metallic taste in the mouth during the injection is also frequently mentioned. Most of these side effects are mild and resolve shortly after the infusion is completed. However, patients should always report any discomfort to their nurse or doctor immediately.
While there is no known direct chemical interaction between alcohol and Iron Sucrose, it is generally advised to avoid alcohol on the day of your treatment. Alcohol can cause dehydration and may lower your blood pressure, which can compound the hypotensive side effects of the medication. Drinking alcohol could also make it harder for your doctor to distinguish between a reaction to the medication and the effects of alcohol. Always consult your healthcare provider about your alcohol consumption habits. Staying hydrated with water is much more beneficial during your treatment course.
Iron Sucrose is often considered safe during the second and third trimesters of pregnancy if oral iron is not effective. It is classified as Category B, meaning animal studies show no harm, but human data is limited. It is generally avoided in the first trimester unless absolutely necessary. Doctors will weigh the risks of severe anemia, which can harm the baby, against the potential risks of the IV infusion. If prescribed, it is usually administered in a controlled clinical setting to monitor for any allergic reactions.
You will not feel the effects of Iron Sucrose immediately after a single infusion. It takes time for the body to process the iron and use it to build new red blood cells. Most patients begin to show an increase in reticulocytes (young red blood cells) within 7 to 10 days. A noticeable increase in hemoglobin levels and an improvement in symptoms like fatigue usually take 2 to 4 weeks. A full course of treatment, often totaling 1,000 mg of iron, is typically required to see the maximum benefit.
Iron Sucrose is typically given as a specific course of several doses, and stopping early may prevent your anemia from being fully corrected. Since it is not a daily medication like a pill, there is no 'withdrawal' effect, but your iron levels will remain low if the course is not finished. If you are experiencing side effects that make you want to stop, discuss them with your doctor. They may be able to slow down the infusion rate or switch you to a different iron product. Completing the recommended series is vital for long-term health in CKD.
If you miss an appointment for your Iron Sucrose infusion, you should contact your clinic or dialysis center as soon as possible to reschedule. Missing a dose will delay the replenishment of your iron stores and the improvement of your anemia symptoms. Because this medication is given on a specific clinical schedule, your provider will help you get back on track. It is important to stay consistent with your appointments to ensure the treatment is effective. Do not try to 'double up' doses at your next visit.
Weight gain is not a recognized or common side effect of Iron Sucrose. The medication does not contain calories in a significant amount, nor does it affect the metabolic processes that typically lead to fat accumulation. If you notice rapid weight gain or swelling (edema) while taking this medication, it may be related to your underlying kidney condition or fluid retention. Swelling of the hands or feet should be reported to your doctor, as it could indicate a need to adjust your dialysis or other medications. Always track unusual weight changes.
Iron Sucrose can be taken alongside most medications, but it should not be used with oral iron supplements. Taking both can increase the risk of iron overload and decrease the effectiveness of the oral iron. There is also a potential interaction with ACE inhibitors, which might increase the risk of a mild allergic reaction. You should provide your doctor with a full list of all prescriptions, over-the-counter drugs, and herbal supplements you are taking. This allows them to monitor for any specific interactions that could affect your safety.
Yes, Iron Sucrose is available as a generic medication, although the brand name Venofer is very widely used. Generic versions must meet the same FDA standards for safety, strength, and quality as the brand-name product. Because Iron Sucrose is a complex 'non-biological' drug, the manufacturing process for generics is very strictly regulated to ensure the iron-sucrose complex is stable. Your insurance provider or hospital formulary may determine whether you receive the brand name or the generic version. Both are considered therapeutically equivalent for treating iron deficiency.
Other drugs with the same active ingredient (Iron Sucrose)
> Warning: Stop taking Iron Sucrose and call your doctor immediately if you experience any of these.
The primary concern with long-term use of Iron Sucrose is the potential for iron overload. Excess iron is stored in the liver, heart, and endocrine glands. Over time, this can lead to:
As of 2024, Iron Sucrose (Venofer) does not carry an FDA Black Box Warning. However, it does carry significant 'Warnings and Precautions' regarding hypersensitivity reactions. Unlike older iron dextran products, a 'test dose' is not legally mandated by the FDA for Iron Sucrose, but many clinical protocols still recommend observing the patient closely for the first 30 minutes of the first infusion.
Report any unusual symptoms to your healthcare provider. Even mild symptoms should be documented to help your doctor adjust your treatment plan.
To ensure safety and efficacy, your healthcare provider will order regular blood tests:
Iron Sucrose can cause dizziness and hypotension. Patients are advised not to drive or operate heavy machinery for several hours after an infusion until they know how the medication affects them. If you feel lightheaded or faint after a treatment, do not attempt to drive.
There is no direct chemical interaction between Iron Sucrose and alcohol. However, alcohol can dehydrate the body and worsen the hypotensive effects (low blood pressure) of the medication. It is generally recommended to avoid alcohol on the day of your infusion.
Iron Sucrose does not cause a withdrawal syndrome. However, stopping the medication before the full course is completed will likely result in a failure to correct the anemia, leading to a return of fatigue and other symptoms. If treatment must be discontinued due to an allergic reaction, your doctor will switch you to a different class of iron or a different iron complex (like Ferric Carboxymaltose).
> Important: Discuss all your medical conditions, especially any history of liver disease, infections, or previous drug allergies, with your healthcare provider before starting Iron Sucrose.
Because Iron Sucrose is administered intravenously, traditional food interactions involving the stomach (like the 'grapefruit effect') do not occur. However, overall nutritional status is important. A diet high in Vitamin C can theoretically help the body utilize iron once it is released from the sucrose complex, though this is more relevant for oral iron.
For each major interaction, the management strategy involves timing and monitoring. The primary strategy is the cessation of oral iron and the careful timing of blood draws to ensure that laboratory data reflects the patient's physiological state rather than the immediate presence of the drug.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and vitamins.
Patients who have had a mild reaction to other iron complexes (like Ferric Gluconate or Iron Dextran) may be able to tolerate Iron Sucrose, but only under extreme caution. There is a potential for cross-sensitivity among different parenteral iron products because they all share a similar iron-hydroxide core. However, the carbohydrate shell (sucrose vs. dextran vs. carboxymaltose) is often what triggers the specific allergic response.
> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to IV medications, before prescribing Iron Sucrose.
Iron Sucrose is approved for children aged 2 years and older with CKD.
Clinical studies of Iron Sucrose did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Iron Sucrose is specifically designed for this population. No dose adjustment is needed based on GFR. In patients on hemodialysis, the drug is typically administered into the venous line of the dialysis machine at the end of the session to ensure maximum delivery to the body.
In patients with hepatic impairment (Child-Pugh Class B or C), iron should be administered with extreme caution. The liver's ability to produce transferrin (the iron transport protein) may be reduced, leading to higher levels of non-transferrin-bound iron, which can be toxic. Regular monitoring of LFTs and ferritin is mandatory.
> Important: Special populations require individualized medical assessment and frequent monitoring of blood parameters.
| Parameter | Value |
|---|---|
| Bioavailability | 100% (Intravenous) |
| Protein Binding | >90% (as Transferrin) |
| Half-life | ~6 hours (terminal) |
| Tmax | Immediate (end of infusion) |
| Metabolism | Dissociation in the RES |
| Excretion | Renal (Sucrose component ~75%) |
Iron Sucrose is categorized as a Parenteral Iron Replacement agent. It is part of a therapeutic class that includes other IV iron complexes such as:
Compared to iron dextran, Iron Sucrose has a lower molecular weight and a lower risk of anaphylaxis, making it a preferred choice in many clinical settings.